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Abstract
The aim of this systematic review was to collect and summarise all current data on the cost-effectiveness of biological treat-
ment in ulcerative colitis. A literature search was conducted using the Medline, Embase, Centre for Reviews and Dissemination 
databases and included all cost-effectiveness analyses comparing biological treatment with any comparator. We identified 277 
records of which 10 were included in this review. Eighty percent of identified analyses used quality-adjusted life years (QALY) 
as a measure of outcome. The most commonly assessed biological agent was infliximab. Half of the eight economic analyses, 
with QALY as an outcome, showed the cost-effectiveness of biological treatment against the comparator. Incremental cost-ef-
fectiveness ratios (ICER) ranged from 15,748 euro to 450,791 euro. The highest ICER values were observed when biologicals 
were compared with standard care alone. This systematic review revealed that in some cases the biological treatment, despite 
its clinical effectiveness, is too expensive and exceeds the national threshold value. 
Introduction
Ulcerative colitis (UC) is an idiopathic inflammatory 
bowel disease characterised by an inflammatory reac-
tion involving the colonic mucosa [1]. The clinical course 
is unpredictable and marked by alternating periods of 
exacerbation and remission, which may occur sponta-
neously or in response to treatment changes or inter-
current illnesses [2, 3]. Patients with UC have a normal 
life expectancy [1]. The prevalence rate of UC in North 
America and northern Europe varies from 156 to 291 
cases per 100,000 people [4].
The therapy of UC is directed at a rapid resolution 
of symptoms, and subsequently maintenance of symp-
tom-free periods. Lifelong medical treatment and often 
surgery are required. Conventional therapy comprises cor-
ticosteroids, aminosalicylates, and drugs that affect the im-
mune response. Ulcerative colitis has a significant impact 
on quality of life and daily activity, because patients experi-
ence loss of energy, negative self-image, and social fear [3]. 
Until recently, surgery was the only remaining 
choice for patients with moderate-to-severe chronic UC, 
in whom the standard treatment failed or was not tol-
erated. The introduction of biological drugs, such as 
infliximab, adalimumab, or golimumab, which inhibit 
tumour necrosis factor α (TNF-α), has provided a new 
alternative for the management of UC and is expected 
to decrease the rate of colectomies or at least extend 
the time to surgery, compared with standard treatment. 
Tumour necrosis factor α is a proinflammatory 
cytokine found at increased concentrations in the 
blood, colonic tissue, and stools of patients with UC. 
Infliximab, adalimumab, and golimumab are chimeric 
or human monoclonal antibodies that bind with high 
affinity and specificity to human TNF, neutralising its 
biological activity [5–7]. On the one hand, their superior 
efficacy compared with placebo in moderate-to-severe 
non-acute UC has been well established by clinical tri-
als [8–13]. On the other hand, the use of biologicals 
constitutes a heavy burden for the public payer, so it 
can be limited in many countries. It was also expected 
that the introduction of biologicals to the treatment of 
inflammatory bowel diseases would cause a substantial 
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decline in colectomy rates. However, this issue is equiv-
ocal and is still under study. 
Economic analyses are performed to assess the 
cost-effectiveness of the new treatment compared with 
the existing one (comparator). When an additional clin-
ical effect of the new treatment is proven after com-
paring it with the existing treatment in a randomised 
control trial, a cost-effectiveness analysis (CEA) or 
cost-utility analysis (CUA) is carried out. The CEA con-
siders both the costs of therapy and clinical outcomes, 
while the CUA additionally includes the quality of life 
in the form of utility weights. The results are presented 
in the form of life-years gained or quality-adjusted life-
years (QALY) gained (when utility weights are included), 
total costs of therapy including the pharmacotherapy 
costs, and incremental cost-effectiveness ratio (ICER) or 
incremental cost-utility ratio (ICUR). The ICER or ICUR 
values are calculated as the quotient of the difference 
in costs and the difference in effectiveness between the 
new therapy and the comparator. The new therapy is 
deemed cost-effective if it is more effective than the 
comparator, and the ICER or ICUR value is below the 
threshold value (in Poland it equals three times the 
gross domestic product per capita, i.e. 125,955 PLN, 
about 29,000 EUR or 33,000 USD, as of 2016) [14, 15].
When the same clinical effectiveness of the new 
therapy and the comparator is proven, based on results 
of a randomised controlled trial, a cost-minimisation 
analysis (CMA) is performed. The CMA compares the 
costs of the new therapy and the comparator, and it 
does not include the clinical effectiveness because it 
assumes the same clinical effect and safety profile for 
the new therapy and the comparator. The results of the 
CMA are presented as the difference between the new 
treatment total costs and the comparator total costs. If 
this difference is negative (below zero), it means that 
the application of the new therapy instead of the com-
parator generates savings to the payer [14].
The costs in economic analysis are categorised into 
two types: direct or indirect. The direct costs include 
costs directly connected with the treatment, i.e. costs 
of pharmacotherapy, medical devices, diet supplements, 
hospitalisations, diagnostic procedures, laboratory tests, 
and ambulatory care. The indirect costs or productivity 
losses are the labour earnings that are forgone because 
of an adverse health outcome, i.e. illness, death, side ef-
fects, or time spent on treatment. The productivity loss-
es can occur in paid work, but also in unpaid work, such 
as household work, care work, or volunteer work [16]. 
Economic analyses are used during the reimbursement 
process because they provide valuable information for 
decision makers and enable them to allocate the limited 
funds reasonably. Generally, economic analyses are car-
ried out from the public payer’s perspective (direct costs 
incurred by public payer are included), the patients’ per-
spective (direct costs incurred by patients are included), 
or the social perspective (direct and indirect costs are 
included). The discounting is used in economic analysis 
with a time horizon longer than one year, to calculate 
the actual values of costs and outcomes that are likely 
to occur in the future.
Aim
The aim of this systematic review was to collect 
and summarise all data concerning the cost-effective-
ness of biological treatment in UC. We focused on four 
biologicals: infliximab, adalimumab, golimumab, and 
vedolizumab. Their additional clinical effect has been 
proven in randomised clinical trials when compared 
with standard care alone [8–13]. We focused on anal-
yses that compared the biological treatment (alone or 
with standard care) with any other comparator, i.e. pla-
cebo, standard care, surgery, cyclosporine, or another 
biological agent. We also compared the methodologies 
of identified analyses.
Material and methods 
Literature search
To collect data on the cost-effectiveness of biologi-
cal treatment of UC we performed a systematic review 
of the literature on 23 August 2016, using the following 
databases: Centre for Reviews and Dissemination (CRD), 
MEDLINE (via PubMed), and Embase. In the search we 
used the following terms: ulcerative colitis, ulcerative 
disease, and colitis ulcerosa, in order to determine the 
population; the terms: tumor necrosis factor, tumour 
necrosis factor, tnf, biologic, infliximab, remicade, inflec-
tra, remsima, adalimumab, humira, golimumab, simponi, 
vedolizumab, and entyvio, in order to determine inter-
vention; and the terms: cost effectiveness, cost efficacy, 
cost utility, economic evaluation, economic assessment, 
and economic analysis in order to determine endpoints. 
We used a Population, Intervention, Comparison, Out-
come (PICO) scheme to describe the population of in-
terest: P – people affected by UC, we also considered 
studies conducted in subpopulations; I – we considered 
biological treatment with infliximab, adalimumab, go-
limumab, vedolizumab; C – not applicable, we consid-
ered all possible alternative treatments for UC; and O – 
cost-effectiveness analysis.
The systematic review was performed independent-
ly by two different researchers, giving the same results. 
In case of differences, the authors had to get a con-
sensus on the decision if the specific record should be 
eligible. All (if any) problematic studies included in this 
systematic review are marked.
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Study selection
No date or country filters were used. We included 
papers written in English. We considered original stud-
ies that were primary sources of information about the 
cost-effectiveness of biologicals in UC, and system-
atic reviews that were secondary sources leading (by 
hand-searching) to previously undiscovered cost-effec-
tiveness assessments. We did not include conference 
abstracts, posters, or health technology assessments 
(HTAs). Records were excluded if they involved a differ-
ent intervention (i.e. surgery, pharmacotherapy other 
than biologics), different endpoints (i.e. clinical analysis, 
budget impact analysis, cost assessments), or different 
population (Crohn’s disease, inflammatory bowel dis-
eases other than UC). The selected articles that met the 
inclusion criteria, in accordance with the PICO scheme, 
were included in this review. The records were selected 
in accordance with the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) statement.
Data extraction and presentation
Data from eligible articles were collected. Based on 
the Cochrane Handbook for Systematic Reviews of In-
tervention [17], the following items were collected: first 
author’s name, year of study, population, interventions 
and comparators, study design (type of economic analy-
sis, perspective, time horizon, methods of measuring out-
comes, country, discount rates, currency, cost reference 
date), and results (total costs, total outcomes, ICER value, 
conclusions concerning cost-effectiveness). To facilitate 
the comparison of results, all costs were converted into 
values from the year 2015, using the consumer price in-
dex – a standard and common approach for adjusting 
costs to a specific year. All cost values were presented 
in euros (exchange rates as of 8 September 2016). All 
calculations and data collection were performed using 
Microsoft Excel (Microsoft Corporation, Redmond, WA).
Data synthesis
The results of the identified analyses were grouped 
according to the type of biologicals: infliximab, adalim-
umab, golimumab, and vedolizumab, as well as accord-
ing to the type of measured outcomes. The cost-effec-
tiveness was assessed based on conclusions from each 
study (the ICER value compared with the threshold val-
ue in a particular country). A quantitative analysis was 
not possible because there were significant differences 
in study designs, interventions, and populations. 
Results
The systematic search identified 277 references. After 
removing duplicates, 209 records were left and submitted 
for further assessment based on their abstracts. Out of 
these, 24 records were analysed based on full texts. Next, 
14 records were excluded due to secondary data (system-
atic reviews), different type of publication (HTA reports, 
conference abstracts), or different endpoints. The remain-
ing 10 records were included in this review (Figure 1).
Out of 10 identified economic evaluations, three 
used decision-tree modelling [18–20] and seven were 
based on Markov modelling [21–27]. QALY was the 
endpoint of eight analyses [18, 19, 21–23, 25–27], re-
mission and response was used in one study [24], and 
mucosal healing in another one [20]. The most com-
monly assessed biological agent was infliximab – eight 
studies [18–20, 23–27]. Adalimumab was included in 
four economic evaluations [20, 21, 24, 27], golimumab 
in two [22, 24], while only one analysis was found for 
vedolizumab [20]. The comparators included for bio-
logical agents were: standard/usual care/convention-
al therapy [19, 21–27], cyclosporine [18, 19], surgical 
Figure 1. PRISMA flow diagram showing the re-
cord selection process. Reason A – secondary 
data; reason B – different type of publication; 
reason C – different endpoint
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treatment [18, 19], and another biological agent [20, 
24]. The time horizon varied from 1 year [18, 19, 20, 
24], through five [26, 27] and 10 years [25, 26], to 30 
years [21–23]. Table I presents the characteristics of the 
included studies.
Among eight economic evaluations with QALY as an 
endpoint, four demonstrated the cost-effectiveness of 
the biological agent compared with alternative treat-
ment [18, 19, 25, 26]. The  ICERs (cost per one addition-
al QALY) for the biologicals ranged from 15,748 EUR to 
450,791 EUR (Table II). 
Infliximab, when compared with standard care 
alone, resulted in an ICER value ranging from about 
29,000 EUR to 93,000 EUR – only two studies were 
identified, and the lower ICER value was obtained in the 
study where only patients in remission were included. 
The ICER values were lower when infliximab was com-
pared with cyclosporine (from 24,000 to 26,000 EUR) or 
surgical treatment (16,000 EUR). A biological treatment 
combining infliximab and adalimumab (as a second-line 
treatment) compared with standard care resulted in an 
ICER value of 280,000 EUR, and it was even higher for 
Table I. Characteristics of the included studies
Reference Population Intervention and 
comparators
Study design/methods
Chaudhary,  
2013 [18]
Sever UC adult patients 
hospitalized with  
an acute exacerbation  
of the disease
Infliximab, cyclosporine, 
surgical intervention
Type: CEA, decision-tree; perspective: national payer; horizon: 
1 year; methods of measuring outcomes: QALY; country: 
Netherlands; discount rates: costs 4%, effects 1.5%; currency: 
euro; cost reference date: 2010
Punekar,  
2010 [19]
Moderate/severe UC 
patients hospitalized with 
an acute exacerbation of 
the disease
Standard care, infliximab, 
cyclosporine, surgery
Type: CEA, decision-tree; perspective: public payer; horizon:  
1 year; methods of measuring outcomes: QALY; country: 
England and Wales; discount rates: costs 3.5%, effects 3.5%; 
currency: GBP; cost reference date: 2006–2007
Stawowczyk,  
2016 [21]
Moderate/severe UC 
patients, induction and 
maintenance treatment
Adalimumab + standard 
care, standard care
Type: CEA, Markov; perspective: public payer, social; horizon:  
30 years; methods of measuring outcomes: QALY; country: 
Poland; discount rates: costs 5%, effects 3.5%; currency: euro; 
cost reference date: 2015
Stawowczyk,  
2016 [22]
Moderate/severe UC 
patients, induction and 
maintenance treatment
Golimumab + standard 
care, standard care 
Type: CEA, Markov; perspective: public payer, social; horizon:  
30 years; methods of measuring outcomes: QALY; country: 
Poland; discount rates: costs 5%, effects 3.5%; currency: PLN; 
cost reference date: 2015
Stawowczyk,  
2016 [23]
Moderate/severe UC 
patients, induction and 
maintenance treatment
Infliximab + standard 
care, standard care 
Type: CEA, Markov; perspective: public payer; horizon:  
30 years; methods of measuring outcomes: QALY; country: 
Poland; discount rates: costs 5%, effects 3.5%; currency: PLN; 
cost reference date: 2015
Toor,  
2015 [24]
Moderate/severe UC 
patients, induction and 
maintenance treatment
Conventional therapy, 
infliximab, adalimumab, 
golimumab 50 mg, 
golimumab 100 mg 
Type: CEA, Markov; perspective: public payer; horizon: 1 year; 
methods of measuring outcomes: response, remission; country: 
Canada; discount rates: no; currency: $CAD; cost reference 
date: 2013
Tsai,  
2008 [25]
Moderate/severe UC 
patients, scheduled 
maintenance treatment
Infliximab + standard 
care, standard care
Type: CEA, Markov; perspective: public payer; horizon: 10 years; 
methods of measuring outcomes: QALY; country: England and 
Wales; discount rates: costs 3.5%, effects 3.5%; currency: GBP; 
cost reference date: 2006–2007
Ung,  
2014 [26]
Moderate/moderately 
severe UC patients, 
induction and 
maintenance treatment
Infliximab + standard 
care, standard care 
Type: CEA, Markov; perspective: health system; horizon: 5 and 
10 years; methods of measuring outcomes: QALY, real-life data; 
country: Canada; discount rates: costs 5%, effects 5%; currency: 
USD; cost reference date: 2013
Xie,  
2009 [27]
Moderate-to-severe 
refractory UC patients, 
induction and 
maintenance treatment
Infliximab 5 mg, 
adalimumab, infliximab 
5 mg, infliximab 10 mg, 
usual care 
Type: CEA, Markov; perspective: public payer; horizon: 5 years; 
methods of measuring outcomes: QALY; country: Canada; 
discount rates: costs 5%, effects 5%; currency: CAD; cost 
reference date: 2008
Yokomizo,  
2016 [20]
Moderate-to-severe UC 
patients, induction and 
maintenance treatment
Infliximab 5 mg, 
infliximab 10 mg, 
adalimumab, 
vedolizumab 
Type: CEA, decision tree; perspective: third party’s; horizon: 
1 year; methods of measuring outcomes: remission, mucosal 
healing; country: USA; discount rates: no; currency: USD; cost 
reference date: 2014
UC – ulcerative colitis, CEA – cost-effectiveness analysis, QALY – quality-adjusted life-years.
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the treatment combining infliximab at a dose of 5 mg 
and infliximab at a dose of 10 mg – 451,000 EUR. 
Adalimumab compared with standard care showed 
an ICER value of about 71,000 to 76,000 EUR, while 
treatment with golimumab resulted in a higher ICER 
value of about 87,000 to 91,000 EUR.
If outcomes other than QALY were considered, go-
limumab at a dose of 100 mg had lower cost per re-
Table II. Cost-effectiveness of biologicals for the treatment of ulcerative colitis
Reference Results – original values ICER – 2015 euro values
Chaudhary,  
2013 [18]
Total costs: IFX = 17,062, CSP = 14,784, S = 13,979
QALY: IFX = 0.80, CSP = 0.70, S = 0.58
ICER: IFX vs. CSP = 24,277, IFX vs. S = 14,639
Conclusion: IFX is cost-effective compared with CSP and S
IFX vs. CSP = 26,117
IFX vs. S = 15,748
Punekar,  
2010 [19]
Total costs: S = 17,067, CSP = 18,122, SC = 18,524, IFX = 19,847
QALY: S = 0.58, CSP = 0.70, SC = 0.68, IFX = 0.80
ICER: IFX vs. CSP = 19,545
Conclusion: IFX is cost-effective compared with CSP, S, SC
IFX vs. CSP = 24,171
Stawowczyk, 
2016 [21]
Total costs, public payer: ADA = 20,598, SC = 9950
Total costs, social: ADA = 93,765, SC = 83,770
QALY: ADA = 15.204, SC = 15.064
ICER public payer: ADA vs. SC = 76,120
ICER social: ADA vs. SC = 71,457
Conclusion: ADA is not cost-effective compared with SC
Public payer perspective: 
ADA vs. SC = 76,120
Social perspective: 
ADA vs. SC = 71,457
Stawowczyk, 
2016 [22]
Total costs, public payer: GOL = 93,321, SC = 45,502
Total costs, social: GOL = 302,848, SC = 257,092
QALY: GOL = 19.241, SC = 19.118
ICER public payer GOL vs. SC = 391,252
ICER social: GOL vs. SC = 374,377
Conclusion: GOL is not cost-effective compared with SC
Public payer perspective: 
GOL vs. SC = 90,757
Social perspective: 
GOL vs. SC = 86,842
Stawowczyk, 
2016 [23]
Total costs: IFX = 99,522, SC = 29,642
QALY: IFX = 14.296, SC = 14.123
ICER: IFX vs. SC = 402,420
Conclusion: IFX is not cost-effective compared with SC
IFX vs. SC = 93,347
Toor,  
2015 [24]
Cost per 1 year additional remission / response: GOL 50 vs.  
SC = 1048/770, GOL 100 vs. SC = 935/701, IFX vs. SC = 1975/1311,  
ADA vs. SC = 7,430/2361, IFX vs. GOL 100 = 14,659/4753,  
ADA vs. GOL 100 = –3324/–4019
Conclusions: GOL 100 and GOL 50 have the lowest cost of additional  
1 year of remission and response; IFX has the highest efficacy, but also 
high costs, ADA produced the highest cost/remission and response
Cost per 1 year additional remission/response: 
GOL 50 vs. SC = 758/557
GOL 100 vs. SC = 677/507
IFX vs. SC = 1429/949
ADA vs. SC = 5377/1709
IFX vs. GOL 100 = 10,609/3440
ADA vs. GOL 100 = –2406/–2909
Tsai,  
2008 [25]
Responders only: Total costs: IFX = 66,460, SC = 45,798
QALY: IFX = 4.591, SC = 3.838
ICER: IFX vs. SC = 27,424
Remission only: Total costs: IFX = 53,874, SC = 46,259
QALY: IFX = 4.154, SC = 3.767
ICER: IFX vs. SC = 19,696
Conclusion: IFX is cost-effective compared with SC
Responders only: 
IFX vs. SC = 40,065
Remission only: 
IFX vs. SC = 28,774
Ung,  
2014 [26]
ICER: IFX vs. SC = 79,000 (5 years), 64,000 (10 years)
Conclusion: IFX is cost-effective compared with SC
IFX vs. SC = 73,085 (5 years), 59,208 (10 years)
Xie,  
2009 [27]
ICER: IFX ADA vs. SC = 358,088, IFX IFX vs. SC = 575,540
Conclusion: Anti-TNF-α therapies are not cost-effective compared 
with SC
IFX ADA vs. SC = 280,472
IFX IFX vs. SC = 450,791
Yokomizo,  
2016 [20]
Cost per MH achieved: IFX 5 = 99,171, IFX 10 = 123,653, ADA = 316,378, 
VED = 301,969
Cost per 1 additional MH achieved: IFX 5 vs. IFX 10 = 1,243,310,  
IFX 5 vs. ADA – dominated, IFX 5 vs. VED – dominated
Conclusions: IFX is the most cost-effective treatment option
Cost per 1 additional MH achieved: 
IFX 5 vs. IFX 10 = 1,133,201
IFX 5 vs. ADA – dominated
IFX 5 vs. VED – dominated
IFX – infliximab, ADA – adalimumab, GOL – golimumab, GOL 50 – golimumab 50 mg, GOL 100 – golimumab 100 mg, VED – vedolizumab, SC – standard/usual 
care/conventional treatment, S – surgery, CSP – cyclosporine, MH – mucosal healing, ICER – incremental cost-effectiveness ratio, QALY – quality adjusted life 
years.
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mission and per response than golimumab at a dose 
of 50 mg, infliximab, and adalimumab. When the cost 
per mucosal healing achieved was taken into consider-
ation, infliximab at a dose of 5 mg had a lower value 
than infliximab at a dose of 10 mg, adalimumab, and 
vedolizumab.
Infliximab treatment seems to be a cost-effective 
treatment option for patients with moderate-to-severe 
UC when compared to cyclosporine or surgery. The ICER 
value for infliximab, as well as for adalimumab and go-
limumab, compared with standard care alone, exceed-
ed the threshold value, but infliximab turned out to be 
cost-effective when only patients with clinical remis-
sion or only patients with response were considered. 
The highest ICER value was observed when infliximab 
was used with adalimumab (adalimumab used in all pa-
tients after failure of infliximab) or when higher dose of 
infliximab (10 mg) was used in all patients after failure 
of infliximab 5 mg.
There is a need for further economic evaluations for 
vedolizumab. This biological agent was assessed only 
in one cost-effectiveness analysis with remission and 
mucosal healing as the outcomes, and compared with 
infliximab.
Discussion
This review focused on the economic analyses con-
cerning the use of biological agents in UC. We collect-
ed and summarised all current data on the cost-effec-
tiveness of infliximab, adalimumab, golimumab, and 
vedolizumab. The treatment of moderate-to-severe UC 
patients with biological agents is effective but costly. 
Despite the high cost of the drug, in some cases this 
is the only possible and effective way of treatment. 
The biological agents are used not only to induce re-
mission of the disease or to treat acute exacerbations, 
but they are also applied in maintenance treatment to 
prolong the remission-free period. It is recommended 
to use biologics for as long as the patient responds 
to treatment, but it generates a huge burden to the 
public payer.
We included studies concerning different biologicals 
and comparators, different outcomes (mainly QALY, but 
also remission, response, and mucosal healing), differ-
ent perspectives (public payer, social), and different 
decision models (Markov, decision-tree). The selected 
economic analyses for biological treatment assessed 
its cost-effectiveness compared with standard care, cy-
closporine treatment, surgical intervention, or another 
biological agent. Half of the selected studies demon-
strated the cost-effectiveness of biologicals. Due to the 
very diverse methods used in the selected studies, it 
was impossible to conduct a meta-analysis of the re-
sults. The highest number of economic analyses – three 
– was found for Canada (two out of three used QALY as 
an outcome and one used remission and response) and 
Poland (all three used QALY as an outcome). The results 
of the conducted analyses for biological treatment in 
Canada were not consistent – one analysis [26] showed 
that infliximab is a cost-effective treatment option 
compared with standard care and one [27] proved that 
anti-TNF-α therapies are not cost-effective compared 
with standard care. Conclusions for all three economic 
analyses, conducted for three different biologicals used 
in Poland, are consistent – infliximab, adalimumab, and 
golimumab turned out not to be cost-effective com-
pared with standard care alone [21–23].
We found other reviews of the literature concerning 
the cost-effectiveness of biologicals in UC [28–32]. In 
her review, Bodger [28] included not only the economic 
analyses for biological agents, but also for 5-aminosa-
licylates, oral corticosteroids, and surgery used in UC, 
and found only one study for infliximab [25], which was 
also included in our review. The same study was also 
identified in a review by Di Sabatino et al. [29], who 
additionally included the HTA report for infliximab, and 
in a review by Odes and Greenberg [31], who also iden-
tified economic analyses made by Tsai et al. [25] and 
Xie et al. [27]. Huoponen and Blom [30] included in their 
search the widest range of biological agents used in 
UC: infliximab, adalimumab, golimumab, certolizumab, 
natalizumab, and vedolizumab. No studies other than 
the ones included in our review [18, 19, 25–27] were 
identified, besides the HTA reports for infliximab and 
adalimumab (not included in our review due to different 
inclusion criteria). Xie [32] carried out a systematic re-
view only for adalimumab used in UC and identified two 
conference abstracts (not included in our review due to 
different inclusion criteria) and one full-text economic 
analysis [27], which was included in our review.
The following economic analyses identified in our 
review were not included in other systematic reviews: 
Stawowczyk et al. [21], Stawowczyk et al. [22], Stawow-
czyk et al. [23], Toor et al. [24], and Yokomizo et al. [20].
Our systematic review encompassed the main bi-
ological agents that are registered for use in the treat-
ment of UC, i.e. infliximab, adalimumab, vedolizumab, 
and golimumab. We searched not only Medline but also 
the Embase and CRD databases, and we did not use any 
time and language limits. This allowed us to examine 
data unidentified in previous systematic reviews. The 
search was conducted in compliance with the PRISMA 
statement to ensure correct methodology and clarity 
of the record selection process. We also recalculated 
costs to euro values as of 2015 to ensure the best com-
parability. 
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The comparison of conclusions concerning the 
cost-effectiveness in particular studies included in the 
systematic review is difficult because different thresh-
old values are used in different countries. For example, 
the threshold value for Poland, which is 125,955 PLN 
(about 29,000 EUR or 33,000 USD) in the year 2016, is 
one of the lowest in Europe. Additionally, some coun-
tries have special thresholds or reimbursement criteria 
for innovative drugs. The cost of biological drugs and 
other costs can vary significantly among countries.  
The treatment methods used in selected economic 
evaluations differed significantly. Some analyses as-
sumed only induction treatment of acute exacerbation, 
others also included maintenance treatment which is 
recommended by clinical guidelines. The use of a bio-
logical agent after a failure of treatment with another 
one was rarely included in the economic analyses. Only 
two [21, 22] of the identified economic evaluations in-
cluded indirect costs of the disease.
Conclusions
The biological drug that was assessed most often is 
infliximab, while only one economic analysis, with QALY 
as an outcome, was found for golimumab and adalim-
umab as a first-line treatment. There were no studies 
carried out for vedolizumab. The results of our review 
demonstrate a need for further cost-effectiveness stud-
ies, especially for the biological drugs used in UC.
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